334 related articles for article (PubMed ID: 19914319)
61. HIV pharmacology: barriers to the eradication of HIV from the CNS.
McGee B; Smith N; Aweeka F
HIV Clin Trials; 2006; 7(3):142-53. PubMed ID: 16880170
[TBL] [Abstract][Full Text] [Related]
62. Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier.
Robillard KR; Hoque T; Bendayan R
J Pharmacol Exp Ther; 2012 Jan; 340(1):96-108. PubMed ID: 21990609
[TBL] [Abstract][Full Text] [Related]
63. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting.
Mahajan HS; Mahajan MS; Nerkar PP; Agrawal A
Drug Deliv; 2014 Mar; 21(2):148-54. PubMed ID: 24128122
[TBL] [Abstract][Full Text] [Related]
64. Strategies for transporting nanoparticles across the blood-brain barrier.
Zhang TT; Li W; Meng G; Wang P; Liao W
Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
[TBL] [Abstract][Full Text] [Related]
65. Directing the Antiretroviral Drugs to the Brain Reservoir: A Nanoformulation Approach for NeuroAIDS.
Nabi B; Rehman S; Pottoo FH; Baboota S; Ali J
Curr Drug Metab; 2021; 22(4):280-286. PubMed ID: 32964821
[TBL] [Abstract][Full Text] [Related]
66. Lipid Nanocarriers for Neurotherapeutics: Introduction, Challenges, Blood-brain Barrier, and Promises of Delivery Approaches.
Aslam M; Javed MN; Deeb HH; Nicola MK; Mirza MA; Alam MS; Akhtar MH; Waziri A
CNS Neurol Disord Drug Targets; 2022; 21(10):952-965. PubMed ID: 34967302
[TBL] [Abstract][Full Text] [Related]
67. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
68. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients.
Langford D; Marquie-Beck J; de Almeida S; Lazzaretto D; Letendre S; Grant I; McCutchan JA; Masliah E; Ellis RJ
J Neurovirol; 2006 Apr; 12(2):100-7. PubMed ID: 16798671
[TBL] [Abstract][Full Text] [Related]
69. Nanobiotechnology-based drug delivery to the central nervous system.
Jain KK
Neurodegener Dis; 2007; 4(4):287-91. PubMed ID: 17627131
[TBL] [Abstract][Full Text] [Related]
70. Could differential virological characteristics account for ongoing viral replication and insidious damage of the brain during HIV 1 infection of the central nervous system?
Vissers M; Stelma FF; Koopmans PP
J Clin Virol; 2010 Dec; 49(4):231-8. PubMed ID: 20833583
[TBL] [Abstract][Full Text] [Related]
71. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
72. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs.
Sharma P; Garg S
Adv Drug Deliv Rev; 2010 Mar; 62(4-5):491-502. PubMed ID: 19931328
[TBL] [Abstract][Full Text] [Related]
73. Nanocarriers for Effective Brain Drug Delivery.
Comoglu T; Arisoy S; Akkus ZB
Curr Top Med Chem; 2017; 17(13):1490-1506. PubMed ID: 28017157
[TBL] [Abstract][Full Text] [Related]
74. Potential of polymeric nanoparticles in AIDS treatment and prevention.
Khalil NM; Carraro E; Cótica LF; Mainardes RM
Expert Opin Drug Deliv; 2011 Jan; 8(1):95-112. PubMed ID: 21143001
[TBL] [Abstract][Full Text] [Related]
75. HIV in the brain: an interview with Dr. Michael Wool, UCLA researcher.
Wool M
Posit Dir News; 1998 Jan; 10(1):18-24. PubMed ID: 11365052
[TBL] [Abstract][Full Text] [Related]
76. Targeting of AIDS related encephalopathy using phenylalanine anchored lipidic nanocarrier.
Vyas A; Jain A; Hurkat P; Jain A; Jain SK
Colloids Surf B Biointerfaces; 2015 Jul; 131():155-61. PubMed ID: 25988279
[TBL] [Abstract][Full Text] [Related]
77. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier.
Kuo YC; Lee CL
Colloids Surf B Biointerfaces; 2012 Feb; 90():75-82. PubMed ID: 22024400
[TBL] [Abstract][Full Text] [Related]
78. Physical and Metabolic Integrity of the Blood-Brain Barrier in HIV Infection: A Special Focus on Intercellular Junctions, Influx and Efflux Transporters and Metabolizing Enzymes.
Shawahna R
Curr Drug Metab; 2015; 16(2):105-23. PubMed ID: 26179607
[TBL] [Abstract][Full Text] [Related]
79. Laser-enhanced drug delivery of antiretroviral drugs into human immunodeficiency virus-1 infected TZMbl cells.
Malabi R; Lebohang Manoto S; Ombinda-Lemboumba S; Maaza M; Mthunzi-Kufa P
J Biophotonics; 2019 Oct; 12(10):e201800424. PubMed ID: 31140728
[TBL] [Abstract][Full Text] [Related]
80. Chapter 12- Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option.
Destache CJ
Prog Brain Res; 2009; 180():225-33. PubMed ID: 20302837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
